NASDAQ:AUTL Autolus Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Autolus Therapeutics Ltd - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.36 -0.33 (-2.60 %) (As of 09/24/2020 09:53 AM ET) Add Compare Share Today's Range$12.36Now: $12.36▼$12.4350-Day Range$12.36MA: $14.58▼$16.1752-Week Range$3.00Now: $12.36▼$17.19Volume200 shsAverage Volume78,767 shsMarket Capitalization$555.95 millionP/E RatioN/ADividend YieldN/ABeta1.96 ProfileAnalyst RatingsChartCompetitorsEarningsInstitutional OwnershipHeadlinesShort InterestSocial Media Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingAutolus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.33, Autolus Therapeutics has a forecasted upside of 115.4% from its current price of $12.69.Amount of Analyst CoverageAutolus Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesAutolus Therapeutics has received 183 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAutolus Therapeutics has received 190 “underperform” votes. (Add your “underperform” vote.)Community SentimentAutolus Therapeutics has received 50.94% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Autolus Therapeutics and other stocks. Vote “Outperform” if you believe AUTL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AUTL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAutolus Therapeutics does not currently pay a dividend.Dividend GrowthAutolus Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 30.30% of the stock of Autolus Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Autolus Therapeutics are expected to decrease in the coming year, from ($2.63) to ($3.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Autolus Therapeutics is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Autolus Therapeutics is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAutolus Therapeutics has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.40 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUTL Previous Symbol CUSIPN/A CIKN/A Webwww.autolus.com Phone44-20-3829-6230Debt Debt-to-Equity Ratio0.09 Current Ratio9.12 Quick Ratio9.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.91 million Price / Sales191.05 Cash FlowN/A Price / Cash FlowN/A Book Value$5.67 per share Price / Book2.18Profitability EPS (Most Recent Fiscal Year)($2.88) Net Income$-123,850,000.00 Net Margins-10,518.19% Return on Equity-48.60% Return on Assets-41.10%Miscellaneous EmployeesN/A Outstanding Shares44,980,000Market Cap$555.95 million Next Earnings Date11/5/2020 (Estimated) OptionableNot Optionable $12.36 -0.33 (-2.60 %) (As of 09/24/2020 09:53 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AUTL News and Ratings via Email Sign-up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions How has Autolus Therapeutics' stock price been impacted by Coronavirus? Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AUTL shares have increased by 82.6% and is now trading at $12.36. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Autolus Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Autolus Therapeutics. When is Autolus Therapeutics' next earnings date? Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Autolus Therapeutics. How were Autolus Therapeutics' earnings last quarter? Autolus Therapeutics Ltd - (NASDAQ:AUTL) issued its earnings results on Thursday, August, 6th. The company reported ($0.62) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.71) by $0.09. Autolus Therapeutics had a negative return on equity of 48.60% and a negative net margin of 10,518.19%. View Autolus Therapeutics' earnings history. What price target have analysts set for AUTL? 7 analysts have issued 1-year price targets for Autolus Therapeutics' shares. Their forecasts range from $24.00 to $38.00. On average, they expect Autolus Therapeutics' share price to reach $27.33 in the next year. This suggests a possible upside of 121.1% from the stock's current price. View analysts' price targets for Autolus Therapeutics. Who are some of Autolus Therapeutics' key competitors? Some companies that are related to Autolus Therapeutics include Kodiak Sciences (KOD), Sorrento Therapeutics (SRNE), Revolution Medicines (RVMD), SpringWorks Therapeutics (SWTX), Mesoblast (MESO), Editas Medicine (EDIT), BAVARIAN NORDIC/S (BVNRY), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Beam Therapeutics (BEAM), Cortexyme (CRTX), Sangamo Therapeutics (SGMO), Coherus Biosciences (CHRS), Kymera Therapeutics (KYMR) and Compugen (CGEN). View all competitors. What other stocks do shareholders of Autolus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), Gilead Sciences (GILD), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV), Sarepta Therapeutics (SRPT), AbbVie (ABBV) and GW Pharmaceuticals PLC- (GWPH). Who are Autolus Therapeutics' key executives? Autolus Therapeutics' management team includes the following people: Dr. Christian Martin Itin, Chairman & CEO (Age 55)Dr. Martin Pulé, Founder, Sr. VP & Chief Scientific Officer (Age 47)Mr. Andrew J. Oakley, CFO & Sr. VP (Age 57)Mr. Christopher Vann, Sr. VP & COO (Age 55)Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 54) When did Autolus Therapeutics IPO? (AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers. What is Autolus Therapeutics' stock symbol? Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL." Who are Autolus Therapeutics' major shareholders? Autolus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Artal Group S.A. (0.89%), Alyeska Investment Group L.P. (0.60%), FMR LLC (0.20%), FMR LLC (0.20%), Opaleye Management Inc. (0.13%) and Trexquant Investment LP (0.10%). Which institutional investors are selling Autolus Therapeutics stock? AUTL stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, FMR LLC, FMR LLC, Artal Group S.A., Alyeska Investment Group L.P., Tudor Investment Corp Et Al, Goldman Sachs Group Inc., and Advisor Group Holdings Inc.. Which institutional investors are buying Autolus Therapeutics stock? AUTL stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Trexquant Investment LP, California Public Employees Retirement System, Jane Street Group LLC, New York State Common Retirement Fund, and UBS Group AG. How do I buy shares of Autolus Therapeutics? Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Autolus Therapeutics' stock price today? One share of AUTL stock can currently be purchased for approximately $12.36. How big of a company is Autolus Therapeutics? Autolus Therapeutics has a market capitalization of $555.95 million and generates $2.91 million in revenue each year. The company earns $-123,850,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis. What is Autolus Therapeutics' official website? The official website for Autolus Therapeutics is www.autolus.com. How can I contact Autolus Therapeutics? Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
